Metabolic Research
Tirzepatide + AOD-9604 Stack — GLP-1 Weight Loss Peptide Stack Research
Pairs one GLP-1 class compound with a non-GLP-1 lipolytic fragment. Only one GLP-1 is ever included — never Tirzepatide with Semaglutide or Retatrutide.
Total program: 12 weeks · 2 individual vials
Why these peptides are researched together
Tirzepatide and AOD-9604 act through unrelated pathways. Tirzepatide activates GIP and GLP-1 receptors, which govern appetite and insulin signaling. AOD-9604 is a modified fragment of growth hormone (176–191) studied for fat breakdown (lipolysis) without raising IGF-1. The pairing combines an appetite and insulin pathway with a fat-cell pathway.
Each peptide at a glance
- Tirzepatide: Dual GIP/GLP-1 receptor agonist with large published clinical trials.
- AOD-9604: Modified hGH fragment 176–191 studied in lipolysis models.
How the schedules fit together
One weekly, one daily: Tirzepatide is drawn once per week on a fixed day and steps up every 4 weeks on its chart; AOD-9604 is drawn once daily, usually in the morning. Both run the full 12-week program. The two are kept in separate syringes because GLP-1 formulations are generally not mixed with other compounds.
What the research shows
Tirzepatide alone has strong randomized-trial evidence (SURMOUNT program).
Still unproven
AOD-9604 human evidence is limited, and no trial has tested this combination.
FAQs
What is the Tirzepatide + AOD-9604 Stack?
Pairs one GLP-1 class compound with a non-GLP-1 lipolytic fragment. Only one GLP-1 is ever included — never Tirzepatide with Semaglutide or Retatrutide.
What's in the Tirzepatide + AOD-9604 Stack?
The Tirzepatide + AOD-9604 Stack combines Tirzepatide and AOD-9604, each in its own vial. Tirzepatide: Dual GIP/GLP-1 receptor agonist with large published clinical trials. AOD-9604: Modified hGH fragment 176–191 studied in lipolysis models.
What does the Tirzepatide + AOD-9604 Stack do?
Tirzepatide and AOD-9604 act through unrelated pathways. Tirzepatide activates GIP and GLP-1 receptors, which govern appetite and insulin signaling. AOD-9604 is a modified fragment of growth hormone (176–191) studied for fat breakdown (lipolysis) without raising IGF-1. The pairing combines an appetite and insulin pathway with a fat-cell pathway.
What is the Tirzepatide + AOD-9604 Stack dosage?
The amounts for each peptide are listed week by week in the dosing table on this page, taken from each peptide's full dosing chart, with units on a 100-unit syringe and exact vial counts for the full 12-week program.
How long is the Tirzepatide + AOD-9604 Stack?
The Tirzepatide + AOD-9604 Stack is laid out as a 12-week research program. One weekly, one daily: Tirzepatide is drawn once per week on a fixed day and steps up every 4 weeks on its chart; AOD-9604 is drawn once daily, usually in the morning. Both run the full 12-week program. The two are kept in separate syringes because GLP-1 formulations are generally not mixed with other compounds.
What does research show about the Tirzepatide + AOD-9604 Stack?
Tirzepatide alone has strong randomized-trial evidence (SURMOUNT program). Still unproven: AOD-9604 human evidence is limited, and no trial has tested this combination.
Sources
- Meto — The 7 Most Popular Peptide Stacks: What the Science Actually Says
- Dr. Henry Sobo, MD — GLP-1, Anti-Aging and Longevity: The Latest Research
- PubMed — Tirzepatide SURMOUNT-1 trial
- PubMed — AOD-9604 research
Other peptide stacks
- Wolverine Stack
- GLOW Peptide Stack
- KLOW Peptide Stack
- CJC-1295 + Ipamorelin Stack
- Tesamorelin + Ipamorelin Stack
- Semax + Selank + NAD+ Stack
- Mitochondrial Peptide Stack
- AOD-9604 + MOTS-c Stack
- Epitalon + Pinealon Stack
Educational research reference only. Not medical advice or individualized guidance.